JelikaLite

JelikaLite operates in medical devices and digital health, focusing on pediatric neurological care and autism spectrum disorder. Its stated product concept, Cognilum, differentiates itself through a combination of non-invasive near-infrared light stimulation, sensor-based data collection, and machine-learning personalization in a wearable format. The described care process spans assessment, treatment and data collection, and personalized recommendations. No distinct competitors are identified in the company’s comparable-company information; the entries there repeat JelikaLite itself, so naming them as competitors would be misleading. The company is private, has four recorded funding rounds totaling $930,121, and its latest recorded financing was a $50,000 grant in April 2023. Cognilum is still under development and is not FDA-approved for autism, making clinical validation and regulatory progress important factors in evaluating its eventual position in the pediatric neurotechnology market.

JelikaLite’s financing history shows early-stage development supported by a mix of crowdfunding, grants, and seed investment. It raised $624,121 through equity crowdfunding on December 27, 2021, then received a $256,000 National Science Foundation grant on April 27, 2022. The February 1, 2023 Seed round involved Mount Sinai Innovation Partners, Bioverge, and New York Ventures, though no amount is specified. A $50,000 FuzeHub grant on April 20, 2023 was the latest recorded financing. Total funding is $930,121 across four rounds, with no valuation available. The company’s product direction is centered on Cognilum, a wearable combining near-infrared light stimulation, sensors, and machine-learning personalization for pediatric neurological health. These data point to an early development phase, with the 2021 crowdfunding and subsequent grants marking the clearest funding inflection points. No later financing or product launch is documented.